Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis

E. R. Dorsey, J. P. Thompson, K. Noyes, A. W. Dick, R. G. Holloway, S. R. Schwid

Research output: Contribution to journalArticlepeer-review

Abstract

Using published data, we quantified the risk and benefits of natalizumab in relapsing multiple sclerosis using quality-adjusted life years (QALYs) as a metric. Over the first 2 years of therapy, the negative health effects from progressive multifocal leukoencephalopathy were small (loss of 0.001 QALYs) relative to the positive effects on relapses and disability resulting in 0.033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days).

Original languageEnglish (US)
Pages (from-to)1524-1528
Number of pages5
JournalNeurology
Volume68
Issue number18
DOIs
StatePublished - May 2007

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis'. Together they form a unique fingerprint.

Cite this